Guardian Pharmacy Services (GRDN) Could Be 12% Undervalued Following Raised Guidance and Q2 Results

Simply Wall St.08-11

Guardian Pharmacy Services (GRDN) drew investor attention after releasing second quarter 2026 results that showed higher sales and net income compared with a year earlier. The company also raised full...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2658963977?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/5021000-choice1-main-header/1585186902955","is_english":true,"pubTime":"2026-08-11 08:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2658963977","market":"sg","top_or_hot":-1,"title":"Guardian Pharmacy Services (GRDN) Could Be 12% Undervalued Following Raised Guidance and Q2 Results","media":"Simply Wall St.","content":"<div>\n<p>Guardian Pharmacy Services (GRDN) drew investor attention after releasing second quarter 2026 results that showed higher sales and net income compared with a year earlier. The company also raised full...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-grdn/guardian-pharmacy-services/news/guardian-pharmacy-services-grdn-could-be-12-undervalued-foll\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guardian Pharmacy Services (GRDN) Could Be 12% Undervalued Following Raised Guidance and Q2 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuardian Pharmacy Services (GRDN) Could Be 12% Undervalued Following Raised Guidance and Q2 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-11 08:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-grdn/guardian-pharmacy-services/news/guardian-pharmacy-services-grdn-could-be-12-undervalued-foll><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Guardian Pharmacy Services (GRDN) drew investor attention after releasing second quarter 2026 results that showed higher sales and net income compared with a year earlier. The company also raised full...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-grdn/guardian-pharmacy-services/news/guardian-pharmacy-services-grdn-could-be-12-undervalued-foll\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4128","symbol_name":"药品零售","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-grdn/guardian-pharmacy-services/news/guardian-pharmacy-services-grdn-could-be-12-undervalued-foll","article_id":"2658963977","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/5021000-choice1-main-header/1585186902955"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-grdn/guardian-pharmacy-services/news/guardian-pharmacy-services-grdn-could-be-12-undervalued-foll","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2658963977","pubTimestamp":1786408990,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Guardian Pharmacy Services (GRDN) drew investor attention after releasing second quarter 2026 results that showed higher sales and net income compared with a year earlier. The company also raised full year revenue guidance.\nSee our latest analysis for Guardian Pharmacy Services.\nThe latest earnings release and raised guidance have come after a strong period for Guardian Pharmacy Services, with a year to date share price return of 40.43% and a 1 year total shareholder return of 108.60%. This...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4128":"药品零售","GRDN":"Guardian Pharmacy Services, Inc.","BK4196":"保健护理服务"},"translate_title":"在上调指导和第二季度业绩后，Guardian Pharmacy Services (GRDN) 的估值可能被低估 12%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRDN":1.5},"content_text":"Guardian Pharmacy Services (GRDN) drew investor attention after releasing second quarter 2026 results that showed higher sales and net income compared with a year earlier. The company also raised full year revenue guidance. See our latest analysis for Guardian Pharmacy Services. The latest earnings release and raised guidance have come after a strong period for Guardian Pharmacy Services, with a year to date share price return of 40.43% and a 1 year total shareholder return of 108.60%. This points to building momentum despite a 1 day share price decline of 5.38% to $41.47. If these results have you looking beyond Guardian Pharmacy Services, it could be a good moment to see what else is gaining attention in healthcare. Take a look at our screener of 43 healthcare AI stocks. Guardian Pharmacy Services looks like a solid operator with growing earnings and higher guidance, yet the share price pullback after a strong run raises a sharper question: Are you paying a fair price for that quality today? AdvertisementMost Popular Narrative: 11.8% Undervalued Guardian Pharmacy Services is trading at $41.47 against a widely followed fair value narrative of $47, which frames the current pullback as a valuation question rather than a simple change in sentiment.  Active but disciplined M&A, supported by a debt free balance sheet, strong cash conversion above 60% and a flexible shelf registration, positions Guardian to accelerate regional density and national scale, driving incremental revenue and operating leverage.  Read the complete narrative. Want to see why this narrative supports a higher price tag for Guardian Pharmacy Services? The key is how future earnings, margins and valuation multiples are expected to interact. Curious which assumptions about revenue mix and profit conversion really carry the fair value? Result: Fair Value of $47 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there are still pressure points that could flip the Guardian Pharmacy Services story, especially if reimbursement terms tighten or if recent acquisitions take longer to reach expected profitability. Find out about the key risks to this Guardian Pharmacy Services narrative. Another View on Guardian Pharmacy Services Valuation While the core narrative for Guardian Pharmacy Services points to an 11.8% discount to fair value at $47, the current P/E of about 39.9x tells a different story. It sits above the US Healthcare industry at 24.9x, its peer average of 39.3x, and a fair ratio of 26x. This signals meaningful downside risk if sentiment cools and the ratio moves toward that fair ratio level. How comfortable are you with paying this kind of premium for the earnings profile on offer? See what the numbers say about this price — find out in our valuation breakdown. NYSE:GRDN P/E Ratio as at Aug 2026Next Steps The story so far on Guardian Pharmacy Services mixes optimism with clear valuation questions, which makes this a moment to look closely at the data yourself. If you want to see what has investors optimistic right now, check the 3 key rewards. Looking for more investment ideas beyond Guardian Pharmacy Services? If Guardian Pharmacy Services has sharpened your focus on valuations and quality, now is the time to expand your watchlist with other targeted ideas before the next move.  Target potential mispricings by checking companies that screen as high quality and potentially overlooked using the screener containing 21 high quality undiscovered gems. Strengthen your downside protection by focusing on businesses that pass rigorous balance sheet and fundamentals checks with the solid balance sheet and fundamentals stocks screener (48 results). Build a more resilient core by shortlisting companies that show lower overall risk scores through the 83 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2658963977","isCrawlerRequest":true}